But the standard in medicine is usually to include the drop-outs, raising the bar for new drugs, and this was the analysis pre-specified in the SHARP protocola nd the one Merck presented.
FORBES: Finally, A Win For Vytorin
2.
Merck and Schering are paying 35 million pounds over eight years ending in 2009 for the SHARP study.